Hilleman Labs to develop vaccinesIllustrative image – not actual.

Hilleman Laboratories has chalked out an investment plan to develop vaccines.

The company is likely to invest Pound 90 million (approx Rs 650 crore) to develop vaccines, including one to treat diarrhoea, by 2017. The company will conduct research for these vaccines in India.

Hilleman Laboratories, a 50:50 JV between MSD Pharmaceuticals and the UK based Wellcome Trust, will collaborate with the Boston based Medicine in Need (MEND) to develop a rotavirus diarrhoea vaccine in India. MEND will provide the company its formulation technology, while MSD will provide the components of its existing rotavirus vaccine.

← All latest storiesBack to top →